CUREVAC N.V. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.33 USD | +0.87% |
|
-4.51% | -44.66% |
| Apr. 26 | UBS Cuts CureVac Price Target to $14 From $18, Maintains Buy Rating | MT |
| Apr. 25 | Leerink Partners Downgrades CureVac to Market Perform From Outperform, Sets Price Target at $4 | MT |
| Sales 2024 * | 71.1M 76.22M | Sales 2025 * | 99.07M 106M | Capitalization | 489M 524M |
|---|---|---|---|---|---|
| Net income 2024 * | -174M -187M | Net income 2025 * | -117M -125M | EV / Sales 2024 * | 5.44 x |
| Net cash position 2024 * | 102M 109M | Net cash position 2025 * | 93.33M 100M | EV / Sales 2025 * | 3.99 x |
| P/E ratio 2024 * |
-2.63
x | P/E ratio 2025 * |
-3.57
x | Employees | 977 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 54.57% |
More Fundamentals
* Assessed data
More news
Latest transcript on CureVac N.V.
More recommendations
More press releases
More news
| 1 day | +0.87% | ||
| 1 week | -4.51% | ||
| Current month | -23.10% | ||
| 1 month | -23.10% | ||
| 3 months | -34.73% | ||
| 6 months | -54.76% | ||
| Current year | -44.66% |
1 week
2.22
2.63
1 month
2.223.16
Current year
2.224.46
1 year
2.2212.36
3 years
2.22125.66
5 years
2.22151.80
10 years
2.22151.80
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 54 | 23-03-27 | |
Pierre Kemula
DFI | Director of Finance/CFO | 50 | 16-10-31 |
Malte Greune
COO | Chief Operating Officer | 59 | 21-06-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Craig Tooman
BRD | Director/Board Member | 58 | 19-05-31 |
Michael Brosnan
BRD | Director/Board Member | 69 | 23-06-18 |
| Director/Board Member | 67 | 22-06-21 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.74% | 17 M€ | -.--% | - | |
| 0.06% | 2 M€ | -.--% | ||
| 0.04% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 2.33 | +0.87% | 837,605 |
| 24-04-25 | 2.31 | -7.97% | 1,242,504 |
| 24-04-24 | 2.51 | -3.46% | 1,084,869 |
| 24-04-23 | 2.6 | +2.77% | 609,966 |
| 24-04-22 | 2.53 | +3.69% | 598,792 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm EDT
More quotes
CureVac AG is a clinical-stage biopharmaceutical company, The Company strives to create transformative medicines to protect and improve peopleâs lives. Fueled by proprietary RNA technology platform combined with two decades of science and manufacturing, The Company is dedicated to creating novel treatments that enable the body to make its own prophylactic and therapeutic drugs.
Calendar
2024-05-21
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
2.183
EUR
Average target price
9.629
EUR
Spread / Average Target
+341.20%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -44.66% | 522M | |
| +1.51% | 42.75B | |
| +48.49% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- CVAC Stock
